Table 2.
RAS synthetic lethal partners and KRAS mutant cell lines in which they have been identified. Synthetic lethal gene inhibition is reported if tested.
| Synthetic lethal genes or pathways | Cell lines | Drug inhibition |
|---|---|---|
| BCL-XL (BCL2L1) (48) | KRAS mutant cell lines from different histologies | MEK inhibitor plus BCL-XL inhibition |
| FGFR1 (49) | KRAS mutant lung cancer | MEK inhibitor plus FGFR1 inhibition |
| CDK4 (50) | KRAS mutant NSCLC | Not tested* |
| AKT (51) | KRAS mutant pancreatic cancer | AKT and glutathione synthesis inhibition |
| TBK1 (52) | KRAS mutant NSCLC | TBK1 inhibition |
| XPO1 (53) | KRAS mutant NSCLC | XPO1 inhibition |
| TAK1 (54) | KRAS mutant colon cancer | 5Z-7-oxozeaenol |
| YAP1 (55) | KRAS pancreatic cancer | Not tested* |
| WT1 (55) | KRAS mutant lung cancer | Not tested* |
| GATA2 (56) | KRAS mutant NSCLC | Not tested* |
| SNAI2 (57) | KRAS mutant colon cancer | Not tested* |
*Drug inhibition of the correspondent synthetic lethal gene has not been tested in in vitro or in vivo studies.